Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial.

Yan H et al.

NCBI PubMed Central · Papers · License: Open Access

computer science education

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 138557
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.